Literature DB >> 15293615

Relevance of assessing quadriceps endurance in patients with COPD.

C Coronell1, M Orozco-Levi, R Méndez, A Ramírez-Sarmiento, J B Gáldiz, J Gea.   

Abstract

The aims of this study were to investigate whether the impairment in endurance of limb muscles is a general finding in chronic obstructive pulmonary disease (COPD) patients, affecting even those with mild-to-moderate disease or relatively normal physical activity. In addition, this study aimed to determine the physiopathology of exhaustion in local endurance tests and whether the reduction in quadriceps endurance can be predicted from muscle strength measurements. A total of 75 volunteers were assigned to one of two groups according to pulmonary function tests: COPD patients or healthy age-matched controls. Functional assessment included both quadriceps strength (maximum voluntary contraction (QMVC)), and quadriceps endurance (contractions against a load equivalent to 10% QMVC until task failure or for up to a limiting time of 30 min (QTlim)). COPD patients showed a decrease of approximately 43%, in QMVC and approximately 77% in QTlim compared with controls. Task failure occurred only in COPD patients and was due to muscle fatigue, since limiting symptoms were associated with a decrease in the median frequency of quadriceps electromyographical signal and a reversible decrease in QMVC. The impairment in skeletal muscle endurance was present even in patients with mild-to-moderate airflow obstruction and individuals with relatively normal physical activity, and was irrespective of lung function variables, anthropometrical data or quadriceps strength. Peripheral muscle endurance was impaired in chronic obstructive pulmonary disease patients, even in those with relatively normal physical activity and mild-to-moderate airflow obstruction. This impairment associated with an early onset of muscle fatigue and could not be predicted from the severity of the disease or the reduction in quadriceps strength.

Entities:  

Mesh:

Year:  2004        PMID: 15293615     DOI: 10.1183/09031936.04.00079603

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  38 in total

Review 1.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

Review 2.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  Muscle atrophy in chronic obstructive pulmonary disease: molecular basis and potential therapeutic targets.

Authors:  Esther Barreiro; Ariel Jaitovich
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 4.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 5.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 6.  Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients.

Authors:  Roberto A Rabinovich; Jordi Vilaró
Journal:  Curr Opin Pulm Med       Date:  2010-03       Impact factor: 3.155

Review 7.  Activity monitoring in chronic obstructive pulmonary disease.

Authors:  Roberto Benzo
Journal:  J Cardiopulm Rehabil Prev       Date:  2009 Nov-Dec       Impact factor: 2.081

8.  Reproducibility of NIRS assessment of muscle oxidative capacity in smokers with and without COPD.

Authors:  Alessandra Adami; Robert Cao; Janos Porszasz; Richard Casaburi; Harry B Rossiter
Journal:  Respir Physiol Neurobiol       Date:  2016-09-19       Impact factor: 1.931

9.  Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial.

Authors:  Carel R van Wetering; Floortje E van Nooten; Stijn J M Mol; Martine Hoogendoorn; Maureen P M H Rutten-Van Mölken; Annemie M Schols
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Factors contributing to muscle wasting and dysfunction in COPD patients.

Authors:  Rob C I Wüst; Hans Degens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.